{"mainPropery":{"diseaseId":9470,"diseaseName":"Amyotrophic lateral sclerosis type 2","hasGardWebPage":false,"isRare":true,"websiteUrl":"https://rarediseases.info.nih.gov/diseases/9470/amyotrophic-lateral-sclerosis-type-2","synonyms":["ALS2"],"synonyms-with-source":[{"name":"ALS2"}],"identifiers":[{"identifierType":"UMLS","identifierId":"C1859807"}]},"diseaseCategories":[],"organizations":[{"resourceID":2652,"resourceName":"The ALS Association","abbreviation":"","address1":"1275 K Street, N.W.","address2":"Suite 250","address3":"","address4":"","address5":"","city":"Washington, DC","state":"","zip":"20005","country":"","phone":"202-407-8580","tty":"","tollFree":"1-800-782-4747","fax":"202-464-8869","email":"alsinfo@alsa-national.org","url":"http://www.alsa.org","freeText":""}],"resource descriptions":[{"id":10,"resourceId":13,"resourceName":"MedlinePlus Genetics","descriptionText":"<a href='http://ghr.nlm.nih.gov/condition=amyotrophiclateralsclerosistype2' target='_blank'>Genetics Home Reference (GHR)</a> contains information on Amyotrophic lateral sclerosis type 2. This website is maintained by the National Library of Medicine.<br />\r\n","resourceClassificationName":"Overview","resourceClassificationSectionName":"Where to Start"},{"id":1526,"resourceId":2158,"resourceName":"Genetic Testing Registry","descriptionText":"The <a href='http://www.ncbi.nlm.nih.gov/gtr/conditions/C1859807' target='_blank'>Genetic Testing Registry</a> (GTR) provides information about the genetic tests for this condition. The intended audience for the GTR is health care providers and researchers. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.<br />\r\n","resourceClassificationName":"Diagnosis","resourceClassificationSectionName":"Testing Resources"},{"id":1702,"resourceId":2165,"resourceName":"Orphanet","descriptionText":"<a href='https://www.orpha.net/data/patho/Pro/en/Emergency_AmyotrophicLateralSclerosis.pdf' target='_blank'>Orphanet Emergency Guidelines</a> is an article which is expert-authored and peer-reviewed that is intended to guide health care professionals in emergency situations involving this condition. &nbsp;","resourceClassificationName":"Treatment","resourceClassificationSectionName":"Management Guidelines"},{"id":1742,"resourceId":2896,"resourceName":"RDCRN - Clinical Research in Amyotrophic Lateral Sclerosis and Related Disorders for Therapeutic Development","descriptionText":"The <a target=\"_blank\" href=\"https://www.rarediseasesnetwork.org/CREATE/index.htm\">Clinical Research in Amyotrophic Lateral Sclerosis and Related Disorders for Therapeutic Development (CREATE) Consortium</a> is an integrated group of academic medical centers, patient support organizations, and clinical research resources dedicated to conducting clinical research involving sporadic and familial forms of amyotrophic lateral sclerosis, frontotemporal dementia (FTD), primary lateral sclerosis (PLS), hereditary spastic paraplegia (HSP), and progressive muscular atrophy (PMA). The CREATE Consortium has a contact registry for patients who wish to be contacted about clinical research opportunities and updates on the progress of the research projects.\r\n<br />\r\n<br />\r\nFor more information on the registry see: <a target=\"_blank\" href=\"https://www.rarediseasesnetwork.org/registry/index.htm\">https://www.rarediseasesnetwork.org/registry/index.htm</a>","resourceClassificationName":"Research","resourceClassificationSectionName":"Patient Registry"},{"id":2135,"resourceId":3342,"resourceName":"Monarch Initiative","descriptionText":"The <a href='https://monarchinitiative.org/disease/OMIM:205100' target='_blank'>Monarch Initiative</a> brings together data about this condition from humans and other species to help physicians and biomedical researchers. Monarch&rsquo;s tools are designed to make it easier to compare the signs and symptoms (phenotypes) of different diseases and discover common features. This initiative is a collaboration between several academic institutions across the world and is funded by the National Institutes of Health. Visit the website to explore the biology of this condition.","resourceClassificationName":"Overview","resourceClassificationSectionName":"In-Depth Information"},{"id":2159,"resourceId":3367,"resourceName":"Patient Services, Inc (PSI)","descriptionText":"<a href='https://www.patientservicesinc.org/patients/access-program' target='_blank'>Patient Services, Inc (PSI)</a> provides financial support and guidance for qualified patients with specific chronic diseases. PSI helps patients find solutions to the social and economic problems confronting patients with chronic conditions.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Financial Resources"},{"id":2340,"resourceId":3583,"resourceName":"Job Accommodation Network","descriptionText":"The <a href='https://askjan.org/disabilities/Amyotrophic-Lateral-Sclerosis-ALS-Lou-Gehrig-s-Disease.cfm?cssearch=1927553_1' target='_blank'>Job Accommodation Network</a> (JAN) has information on workplace accommodations and disability employment issues related to this condition. JAN is a service of the Office of Disability Employment Policy in the U.S. Department of Labor.","resourceClassificationName":"Living With","resourceClassificationSectionName":"Community Resources"}],"overviewQuestion":{"questionId":0,"dateModified":"0001-01-01T00:00:00"},"basicQuestions":[],"references":[],"relatedDiseases":[{"relatedDiseaseId":5786,"relatedDiseaseName":"Amyotrophic lateral sclerosis","relation":"Parent","isRare":true,"hasGardPage":true},{"relatedDiseaseId":11901,"relatedDiseaseName":"Juvenile amyotrophic lateral sclerosis","relation":"Parent","isRare":true,"hasGardPage":true}],"gardCases":[],"news":[{"newsId":680,"dateCreated":"2020-08-28T12:03:00","publishDate":"2020-09-01T00:00:00","title":"NIH Announces New Transformative Research Award Program for ALS","description":"The National Institutes of Health plans to invest $25 million over 5 years in a new program to spur innovative research on amyotrophic lateral sclerosis (ALS), a progressive and fatal neurological disease that weakens and eventually paralyzes voluntary muscles. Accelerating Leading-edge Science in ALS (ALS2) aims to answer critical questions about this disease.","url":"https://www.nih.gov/news-events/news-releases/nih-announces-new-transformative-research-award-program-als","lastModified":"2020-09-03T13:45:00","isFeatured":false},{"newsId":671,"dateCreated":"2020-05-20T13:39:00","publishDate":"2020-05-22T00:00:00","title":"NIH-Supported Research Survey to Examine Impact of COVID-19 on Rare Diseases Community","description":"The NIH-funded Rare Diseases Clinical Research Network (RDCRN) has launched an <a href=\"https://www.rarediseasesnetwork.org/COVIDsurvey \" target=\"_blank\">online research survey</a> to find out how the COVID-19 pandemic is impacting individuals with rare diseases, their families and their caregivers. Your participation can help the rare disease research community shed light on the needs of people with rare diseases during this and other potential health crises, in addition to informing future research efforts. The survey must be completed by December 15, 2020.","url":"https://www.rarediseasesnetwork.org/COVIDsurvey","lastModified":"2020-11-30T14:44:00","isFeatured":false}],"conferences":[],"phenoTypes":[],"medicalProducts":[{"productId":670,"genericName":"Edaravone","tradeName":"Radicava","tradeLink":"https://www.radicava.com/patient/","manufacturer":"","sponsor":"Mitsubishi Tanabe Pharma Corporation","indication":"May 2017, edaravone (Radicava) was approved for the treatment of amyotrophic lateral sclerosis (ALS).","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/radicava","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a617027.html"},{"productId":408,"genericName":"Riluzole (tablet)","tradeName":"Rilutek","tradeLink":"http://products.sanofi.us/rilutek/rilutek.pdf","manufacturer":"","sponsor":"Sanofi","indication":"December 1995, riluzole (Rilutek) was approved for the treatment of patients with amyotrophic lateral sclerosis. Riluzole extends survival and/or time to tracheostomy.","drugInformationLink":"https://druginfo.nlm.nih.gov/drugportal/name/rilutek","medlinePlusLink":"https://medlineplus.gov/druginfo/meds/a696013.html"}],"EncodedName":"Amyotrophic_lateral_sclerosis_type_2"}